Domain Therapeutics (formerly Faust Pharmaceuticals) is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets.
Domain Therapeutics is using its innovative and proprietary technology platform DTect-All™ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-All™ is able to address difficult GPCRs such as orphan and peptidic GPCRs.
The company’s pipeline is composed of new chemical entities ranging from hits to preclinical candidates targeting hot GPCRs for leading indications such as schizophrenia, Parkinson’s disease and diabetes.